Company intelligence / Profile preview

成都药宜立康

Chengdu, Sichuan, China

Ownership: Private
Development stage: Other

Overview

成都药宜立康医药科技有限公司成立于2023年4月，总部位于成都天府国际生物城。公司主要聚焦高质量仿制药与改良及特殊制剂的开发（CRO）和合作共赢的药品上市持有人（MAH）业务。药宜立康建有完备的从专利与立项评估、原料与制剂开发、质量研究、临床研究、注册申报与持有人管理全药学研究学科团队。公司在口服制剂、冻干及注射剂、吸入制剂、经皮给药系统、肠溶缓释制剂、脂质体等特色制剂领域拥有丰富的研发经验。目前，公司已搭建高端制剂研发及成果转化公共技术平台，并与中玉制药等企业合作，其联合申报的硫代硫酸钠注射液已处于上市申请（NDA）阶段。

Therapeutic areas: Other
Modalities: Small molecule
Industry: Biotech

Partnerships

中玉制药（海口）有限公司湖北午时药业股份有限公司

Beyond the preview

Go deeper on 成都药宜立康.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on 成都药宜立康.

Explore the full profile